Evolus Announced Results From The Phase 2 Clinical Study Evaluating The "Extra-Strength" 40U Dose For Extended Duration Of Jeuveau
Portfolio Pulse from Benzinga Newsdesk
Evolus has announced the results from its Phase 2 clinical study evaluating the 'extra-strength' 40U dose for extended duration of Jeuveau. The 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment. The results indicate a similar safety profile to lower dose arms in the study.
November 06, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolus' Phase 2 clinical study results for the 'extra-strength' 40U dose of Jeuveau indicate a duration of 26 weeks and a similar safety profile to lower doses. This could potentially lead to increased usage and sales of Jeuveau.
The positive results from the Phase 2 clinical study of the 'extra-strength' 40U dose of Jeuveau could potentially lead to increased usage and sales of the product. The extended duration of 26 weeks and the similar safety profile to lower doses are positive indicators for the product's market performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100